alexa Double High Risk Atrial Fibrillation Patient´s | Open Access Journals
Arrhythmia: Open Access
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Double High Risk Atrial Fibrillation Patient´s

Antonio L Aguilar-Shea*
Centro de Salud Puerta de Madrid, Spain
*Corresponding Author : Antonio L Aguilar-Shea
Centro de Salud Puerta de Madrid
Avda. del Ejército 61
28802 Alcalá de Henares (Madrid), Spain
Tel: +34918806699
Fax: +34918823392
E-mail:
[email protected]
Received date: April 14, 2016; Accepted date: April 15, 2016; Published date: April 19, 2016
Citation: Aguilar-Shea AL (2016) Double High Risk Atrial Fibrillation Patient´s. Arrhythm Open Access 1:e103. doi:10.4172/atoa.1000e103
Copyright: © Aguilar-Shea AL. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Arrhythmia: Open Access

Editorial
Atrial fibrillation is the most frequent arrhythmia which must be managed properly. As part of the evaluation and treatment, preventing embolism is a key in these patients. The two groups of drugs used to prevent embolism are oral anticoagulants and antiplatelets. The major secondary effect of both of these agents is bleeding, so a balance between preventing embolism and avoiding bleeding must be achieved. To make the correct decision scale CHA2DS2-VASc will help in the aid of embolism prevention and HASBLED scale will help in the bleeding evaluation. CHA2DS2-VASc punctuation equal or over 2 indicates necessity for oral anticoagulation and HASBLED equal or over 3 indicates a high risk of bleeding. The situation of high risk of embolism and high risk of bleeding is not infrequent and requires a correct management.
To give response to the question of what to do with patients with atrial fibrillation with a high risk of embolism and a high risk of bleeding, the main guidelines were reviewed: European Society of Cardiology [1], Uptodate [2], American College of Cardiology/ American Heart Association [3], National Institute for Health and Care Excellence (NICE) [4] and Cochrane Database [5,6]. The conclusions are that the new oral anticoagulants (apixaban, rivaroxaban and dabigatran) are the treatment of choice in these cases because the risk of bleeding of the new oral anticoagulants is lower when compared to warfarin and high risk of bleeding is not a reason for anticoagulant therapy exclusion.
References
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 7706
  • [From(publication date):
    July-2016 - Nov 24, 2017]
  • Breakdown by view type
  • HTML page views : 7662
  • PDF downloads : 44
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords